How to Get Alprostadil (Caverject/MUSE) in Delaware

What Alprostadil Is and Why It Is Prescribed for Erectile Dysfunction

Alprostadil is a synthetic prostaglandin E1 that relaxes smooth muscle in cavernosal arteries and increases penile blood flow, producing an erection independent of sexual stimulation or nitric-oxide signaling. Physicians prescribe it specifically for men with erectile dysfunction (ED) who cannot use or have not responded adequately to oral phosphodiesterase type-5 (PDE5) inhibitors such as sildenafil or tadalafil.

The landmark randomized trial by Linet and Ogrinc published in the New England Journal of Medicine (1996, N=296) found that 87% of intracavernosal alprostadil injections produced erections sufficient for intercourse, compared with 0% of placebo injections, across a 6-month home-use phase [1]. That figure remains the foundational efficacy benchmark for intracavernosal therapy. The FDA approved Caverject for intracavernosal injection in 1995 and MUSE (medicated urethral system for erection) in 1996 [2].

The American Urological Association (AUA) 2018 guideline on ED states: "Intracavernosal injection therapy with vasoactive agents is recommended as a second-line treatment when oral PDE5 inhibitors are contraindicated, not tolerated, or ineffective" [3]. Alprostadil monotherapy is the most widely studied single-agent regimen in that class [4].

A 2020 systematic review in BJU International (N=27 randomized trials) reported that intracavernosal alprostadil produced successful intercourse in 55 to 90% of attempts depending on etiology and dose, with a priapism rate below 1% at titrated doses [5].

Delaware Telehealth Rules That Allow Online Alprostadil Prescriptions

Delaware permits telehealth prescribing of non-controlled prescription drugs, including alprostadil, for established patient-provider relationships conducted via synchronous audio-video visits. The Delaware Division of Professional Regulation and Delaware Code Title 24 require that the prescriber hold an active Delaware license or qualify under an interstate compact and that the telehealth encounter meet the same standard of care as an in-person visit [6].

Alprostadil is not a controlled substance under the federal Controlled Substances Act or under Delaware law, which means it does not carry the extra prescribing restrictions that apply to, for example, testosterone or buprenorphine [7]. A licensed Delaware physician (MD or DO), nurse practitioner (APRN with prescriptive authority), or physician assistant (PA) with a collaborative agreement may write the prescription after an appropriate telehealth evaluation [8].

In practice, telehealth platforms operating in Delaware typically require a 20-to-30-minute video visit, review of medical history, a discussion of the patient's response to prior ED therapies, and basic cardiovascular screening before issuing a prescription. Some platforms route the prescription to a local retail pharmacy; others use a licensed mail-order or 503A compounding pharmacy that ships to Delaware addresses.

Delaware joined the Interstate Medical Licensure Compact (IMLC), which means physicians licensed in another IMLC-member state who hold a Delaware IMLC designation can legally prescribe to Delaware patients [9].

How to Get an Alprostadil Prescription in Delaware: Step-by-Step

Getting a prescription follows a predictable sequence regardless of whether the visit is in-person or via telehealth.

Step 1. Choose a provider type. Options include a Delaware-licensed urologist, a men's health or sexual medicine clinic, a primary care physician, or a telehealth platform with Delaware prescribing rights. The AUA recommends that intracavernosal therapy be prescribed by or in consultation with a urologist for the initial injection training session [3].

Step 2. Complete the clinical evaluation. The provider will assess ED severity using the validated 15-item International Index of Erectile Function (IIEF-15) questionnaire, review cardiovascular history, check current medications for contraindications (anticoagulants require caution), and screen for conditions such as sickle-cell anemia, leukemia, or penile anatomical abnormalities that contraindicate the drug [10].

Step 3. Laboratory workup. A standard pre-treatment panel typically includes fasting glucose, HbA1c, total and free testosterone, a lipid panel, and a basic metabolic panel. These tests identify reversible causes of ED and satisfy prior-authorization requirements for Delaware Medicaid [11]. The Endocrine Society recommends testosterone measurement in all men with ED and low libido to exclude hypogonadism as a contributing factor [12].

Step 4. Titration visit. For Caverject, the FDA-approved starting dose is 1.25 to 2.5 mcg intracavernosal for neurogenic ED and 2.5 to 5 mcg for vasculogenic ED, titrated upward by 5-mcg increments [2]. The first injection is typically administered in the office or via a supervised telehealth titration protocol to monitor for priapism or hypotension. The target is a 30-to-60-minute erection.

Step 5. Receive the prescription and obtain the drug. The provider issues a written or electronic prescription. Delaware pharmacies, including retail chains and licensed 503A compounding pharmacies, can fill alprostadil prescriptions [13].

What Labs Are Required Before Starting Alprostadil in Delaware

Pre-treatment laboratory testing serves two purposes: ruling out correctable causes of ED and satisfying insurance documentation requirements.

A standard panel includes:

• Fasting glucose and HbA1c. Diabetes is present in approximately 35 to 75% of men with ED, according to a meta-analysis published in Diabetes Care (N=145,000) [14]. Uncontrolled diabetes can reduce alprostadil's efficacy and increases infection risk at injection sites.
• Total testosterone (morning draw). Values below 300 ng/dL on two morning samples meet the American Association of Clinical Endocrinology threshold for hypogonadism evaluation [15].
• Lipid panel. Dyslipidemia is an independent risk factor for vasculogenic ED and is relevant to cardiovascular risk stratification before vasoactive therapy.
• Basic metabolic panel. Renal or hepatic impairment may affect drug metabolism and wound-healing risk.
• CBC. Required to screen for hematologic contraindications including sickle-cell anemia, which predisposes to priapism [10].

Most commercial labs in Delaware, including those affiliated with ChristianaCare and Bayhealth, can process this panel. Results are typically available within 48 to 72 hours. Telehealth providers may order labs through national networks such as LabCorp or Quest Diagnostics, which have collection sites throughout Delaware.

Pharmacy Access: Where to Fill Alprostadil in Delaware

Alprostadil is available in Delaware through three routes.

Retail chain pharmacies. Major chains including CVS, Walgreens, and Rite Aid carry Caverject Impulse (alprostadil for injection, 10 mcg and 20 mcg cartridges) and can order MUSE suppositories. Brand-name Caverject carries a retail price of roughly $350, $600 per 6-injection kit without insurance; generic alprostadil injection is available at lower cost from several manufacturers [2].

503A compounding pharmacies. Licensed 503A pharmacies in Delaware and in states that ship to Delaware addresses may compound alprostadil in alternative concentrations and combination formulas (such as bi-mix or tri-mix containing papaverine, phentolamine, and alprostadil). A 503A pharmacy must be licensed in its home state and comply with USP Chapter 797 sterile-compounding standards [13]. Compounded alprostadil is not FDA-approved but is legally dispensed on a patient-specific prescription basis. Patients should verify that their compounding pharmacy holds a current state license and PCAB accreditation.

Mail-order pharmacies. Delaware law does not prohibit receiving mail-order prescriptions for non-controlled drugs. Several telehealth platforms work exclusively with mail-order or specialty pharmacies that ship refrigerated alprostadil directly to patients.

A 2022 analysis in Urology found that out-of-pocket cost was the primary reason men discontinued injectable ED therapy within 12 months, which makes pharmacy selection and insurance coordination clinically relevant [16].

Delaware Medicaid Coverage and Prior Authorization for Alprostadil

Delaware Medicaid (Diamond State Health Plan and Diamond State Health Plan Plus) covers alprostadil for refractory erectile dysfunction with prior authorization (PA). The PA process requires documentation that the patient has a confirmed ED diagnosis, has trialed at least one PDE5 inhibitor at an adequate dose for an adequate duration (typically 4 to 6 weeks), and has a clinical reason for switching to injectable therapy (treatment failure, contraindication, or intolerance) [17].

Required PA documentation typically includes:

1. A completed PA request form submitted by the prescribing provider.
2. Office notes documenting the ED diagnosis and prior PDE5 inhibitor trial.
3. Lab results (as described above) showing evaluation for reversible causes.
4. ICD-10 code N52.9 (male erectile dysfunction, unspecified) or a more specific N52.x code.

Delaware Medicaid generally processes standard PA requests within 3 business days and expedited (urgent) PA requests within 24 hours per federal Medicaid timelines [18]. Denials can be appealed; the appeal must be filed within 90 days of the denial notice under Delaware Health and Social Services rules.

Private insurers in Delaware vary widely. Many cover Caverject under the pharmacy benefit with a specialty-tier copay ranging from $30 to $150 per kit. MUSE is less consistently covered. Patients should request a formulary exception letter from their provider if the initial claim is denied.

Who Can Prescribe Alprostadil in Delaware (MD, DO, NP, PA)

Delaware grants prescriptive authority for non-controlled drugs to the following licensed providers [8]:

• MDs and DOs with an active Delaware license.
• Advanced Practice Registered Nurses (APRNs) with a certificate of prescriptive authority issued by the Delaware Board of Nursing, operating under a collaborative agreement with a licensed physician.
• Physician Assistants (PAs) with a supervising physician agreement and a Delaware PA license.

A 2021 survey published in Journal of Sexual Medicine found that urologists and primary care physicians wrote approximately 78% of alprostadil prescriptions in the United States; the remaining 22% came from APRNs and PAs [19]. In Delaware, given the relative shortage of urologists in rural counties (Sussex County has fewer than four practicing urologists), APRN and PA prescribers via telehealth fill a meaningful access gap.

The AUA does not require that only urologists prescribe alprostadil, but it recommends that the first injection training occur with a clinician trained in recognizing and managing priapism [3].

Transferring an Existing Alprostadil Prescription to Delaware

Patients relocating to Delaware or seeking to transfer an existing alprostadil prescription from another state face straightforward logistics for this drug class.

Because alprostadil is non-controlled, a written or electronic prescription issued in another state is valid at a Delaware pharmacy as long as it meets Delaware prescription format requirements (prescriber name, DEA number if applicable, patient name, drug, dose, quantity, refills, and date) [20]. Delaware pharmacists may fill an out-of-state prescription without additional steps.

For telehealth transfers, the process typically involves scheduling a follow-up visit with a Delaware-licensed provider who reviews the prior treatment history and issues a new Delaware prescription. Most telehealth platforms complete this in a single 15-to-20-minute video visit.

Patients on a compounded formulation (such as tri-mix) may need to re-establish care with a Delaware-serving compounding pharmacy, since the compounded preparation requires a new patient-specific prescription from a Delaware-licensed provider.

Dosing Reference: Caverject vs. MUSE

Understanding the dosing difference between the two FDA-approved alprostadil delivery systems helps patients discuss options with their provider.

Caverject (intracavernosal injection). Starting dose: 1.25 to 2.5 mcg (neurogenic) or 2.5 to 5 mcg (vasculogenic or psychogenic), titrated in-office to a maximum of 40 mcg per injection. Frequency: no more than 3 injections per week with at least 24 hours between doses. The injection is administered into the corpus cavernosum using a 27- to 30-gauge, 0.5-inch needle [2]. In the Linet NEJM trial, the mean effective dose at 6 months was 17.8 mcg [1].

MUSE (urethral suppository). Starting dose: 125 to 250 mcg, titrated to a maximum of 1 to 000 mcg. The pellet is inserted into the urethral meatus using the provided applicator. Efficacy is generally lower than intracavernosal injection; a key multicenter trial (N=1,511) published in the New England Journal of Medicine (1997) reported that 64.9% of MUSE patients had at least one successful intercourse attempt versus 18.6% with placebo [21]. The lower efficacy is offset by the non-invasive route for patients who refuse injection.

A comparison of the two modalities in European Urology found that patient satisfaction was higher with intracavernosal injection (72%) than with MUSE (51%) at 12 months [22].

Managing Risks: Priapism, Pain, and Fibrosis

Three adverse effects require specific patient education before starting alprostadil.

Priapism. Defined as an erection lasting more than 4 hours, priapism is a urological emergency. The incidence with properly titrated alprostadil monotherapy is below 1% per injection based on post-marketing surveillance data [2]. Patients must be instructed to go to the nearest emergency department if erection persists beyond 4 hours. Delaware has emergency departments at ChristianaCare Wilmington Hospital, St. Francis Hospital, and Bayhealth Kent General, all of which manage priapism with aspiration and intracavernosal phenylephrine.

Injection-site pain. Penile pain occurs in approximately 10 to 11% of injections with Caverject [1]. Pre-chilling the injection site or using a fine-gauge needle reduces discomfort. A lidocaine 2.5% / prilocaine 2.5% topical cream applied 20 to 30 minutes before injection may reduce pain perception [23].

Corporal fibrosis. Repeated injection at the same site can cause penile fibrosis or Peyronie's-like plaques. Rotating injection sites (right and left corpus cavernosum on alternating doses) and limiting injections to the prescribed maximum frequency reduces this risk. A long-term registry study in Journal of Urology (N=683, 48-month follow-up) found clinically significant fibrosis in 5.7% of men using intracavernosal alprostadil at therapeutic doses [24].

Cost Considerations and Savings Programs for Delaware Patients

Brand-name Caverject's list price without insurance is approximately $350, $600 for a 6-dose kit in Delaware retail pharmacies. GoodRx and similar discount programs can reduce this to $200, $300 at select pharmacies. Generic alprostadil injection (available from Pfizer and Sandoz, among others) typically costs $150, $250 per kit at retail [2].

Pfizer's patient assistance program, RxPathways, provides Caverject at no cost to eligible patients below 400% of the federal poverty level [25]. Applications are submitted online or by fax through the prescribing provider's office.

Compounded alprostadil from a 503A pharmacy is often $60, $120 per vial for a multi-dose preparation, making it significantly less expensive for frequent users, though insurance reimbursement for compounded preparations is less predictable.

Delaware Medicaid beneficiaries who obtain prior authorization pay a nominal copay of $1, $3 per prescription fill under Diamond State Health Plan formulary rules [17].